AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Phio Pharmaceuticals Corp. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG0024FKDB4
0.85▼ 0.02 (-2.30%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
—
Trading Information
Previous Close
0.87
Day's Range
0.85 – 0.90
52-Week Range
0.81 – 4.19
Volume
29.2K
Avg Volume
94.7K
Share Statistics
Shares Outstanding
Employees
6
Exchange
XNAS
Listed
2012-05-10
Share count as of August 4, 2026

Phio Pharmaceuticals Corp. Common Stock (PHIO) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Phio Pharmaceuticals Corp. Common Stock (PHIO)
What is Phio Pharmaceuticals Corp. Common Stock's Market Cap?
Phio Pharmaceuticals Corp. Common Stock's Market Cap is $9.9M, based on as-reported figures from SEC (XBRL) filings.
What is Phio Pharmaceuticals Corp. Common Stock's Net Income (TTM)?
Phio Pharmaceuticals Corp. Common Stock's Net Income (TTM) is -$12.9M, based on as-reported figures from SEC (XBRL) filings.
What is Phio Pharmaceuticals Corp. Common Stock's EBITDA?
Phio Pharmaceuticals Corp. Common Stock's EBITDA is -$13.5M, based on as-reported figures from SEC (XBRL) filings.
What is Phio Pharmaceuticals Corp. Common Stock's Diluted EPS (TTM)?
Phio Pharmaceuticals Corp. Common Stock's Diluted EPS (TTM) is -1.11, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · PHIOAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating expenses:
Research and development
General and administrative
Total operating expenses
Operating loss
Interest income, net
Other income (expense), net
Net loss
Basic and diluted (in dollars per share)